ReviewAmerican heart journal plus : cardiology research and practice2026
Is chronic venous disease a marker of systemic cardiovascular risk? A systematic review.
Review in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate whether chronic venous disease (CVeD) is associated with incident hard cardiovascular outcomes in longitudinal cohort studies and whether cardiovascular risk increases with greater venous disease severity. Methods: We conducted a systematic review with exploratory meta-analysis where appropriate. Prospective or retrospective cohort studies enrolling adults with CVeD or proxy venous phenotypes defined at baseline and reporting incident cardiovascular outcomes using multivariable-adjusted time-to-event estimates were included. Prespecified outcomes were myocardial infarction or acute coronary syndrome, ischemic stroke, heart failure, cardiovascular mortality, and all-cause mortality. Results: Five eligible cohort studies were identified. In a Taiwanese nationwide matched cohort, advanced varicose veins were associated with increased risks of heart failure, acute coronary syndrome, ischemic stroke, and all-cause mortality. A South Korean nationwide cohort reported increased incident heart failure among patients with varicose seveins, while a population-based matched cohort demonstrated an increased risk of ischemic stroke. In an Australian cohort severe CVeD was associated with increased major adverse cardiovascular events compared with mild disease, suggesting a severity gradient. Exploratory pooled analyses indicated increased risks of heart failure and ischemic stroke, although heterogeneity across studies was substantial. Mortality estimates were directionally consistent but were interpreted narratively because exposure definitions and severity contrasts differed between studies. Conclusions: Available longitudinal evidence suggests that CVeD is associated with increased risk of subsequent cardiovascular events and all-cause mortality. A consistent severity gradient was observed, with more advanced venous disease associated with greater cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.